[{"id": 1199544, "guidelineid": 100413, "drugid": "RxNorm:321988", "implications": {"CYP2C19": "Normal metabolism"}, "drugrecommendation": "Initiate therapy with recommended starting dose", "classification": "Strong", "phenotypes": {"CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "escitalopram"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1199545, "guidelineid": 100413, "drugid": "RxNorm:321988", "implications": {"CYP2C19": "Reduced metabolism when compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose", "classification": "Strong", "phenotypes": {"CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "escitalopram"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1199546, "guidelineid": 100413, "drugid": "RxNorm:321988", "implications": {"CYP2C19": "Reduced metabolism when compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose", "classification": "Strong", "phenotypes": {"CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "escitalopram"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200074, "guidelineid": 100413, "drugid": "RxNorm:42355", "implications": {"CYP2D6": "Normal metabolism"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.25"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "fluvoxamine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1199541, "guidelineid": 100413, "drugid": "RxNorm:2556", "implications": {"CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "No Recommendation", "phenotypes": {"CYP2C19": "Indeterminate"}, "activityscore": {"CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "citalopram"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1199542, "guidelineid": 100413, "drugid": "RxNorm:321988", "implications": {"CYP2C19": "Increased metabolism when compared to normal metabolizers. Lower plasma concentrations will increase probability of pharmacotherapy failure."}, "drugrecommendation": "Consider an alternative drug not predominantly metabolized by CYP2C19", "classification": "Moderate", "phenotypes": {"CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.", "version": 1, "drug": {"name": "escitalopram"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1199543, "guidelineid": 100413, "drugid": "RxNorm:321988", "implications": {"CYP2C19": "Increased metabolism when compared to normal metabolizers. Lower plasma concentrations will increase probability of pharmacotherapy failure."}, "drugrecommendation": "Consider an alternative drug not predominantly metabolized by CYP2C19", "classification": "Moderate", "phenotypes": {"CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.", "version": 1, "drug": {"name": "escitalopram"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1199534, "guidelineid": 100413, "drugid": "RxNorm:2556", "implications": {"CYP2C19": "Increased metabolism when compared to normal metabolizers. Lower plasma concentrations will increase probability of pharmacotherapy failure."}, "drugrecommendation": "Consider an alternative drug not predominantly metabolized by CYP2C19", "classification": "Moderate", "phenotypes": {"CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.", "version": 1, "drug": {"name": "citalopram"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1199535, "guidelineid": 100413, "drugid": "RxNorm:2556", "implications": {"CYP2C19": "Increased metabolism when compared to normal metabolizers. Lower plasma concentrations will increase probability of pharmacotherapy failure."}, "drugrecommendation": "Consider an alternative drug not predominantly metabolized by CYP2C19", "classification": "Moderate", "phenotypes": {"CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.", "version": 1, "drug": {"name": "citalopram"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1199536, "guidelineid": 100413, "drugid": "RxNorm:2556", "implications": {"CYP2C19": "Normal metabolism"}, "drugrecommendation": "Initiate therapy with recommended starting dose", "classification": "Strong", "phenotypes": {"CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "citalopram"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1199537, "guidelineid": 100413, "drugid": "RxNorm:2556", "implications": {"CYP2C19": "Reduced metabolism when compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose", "classification": "Strong", "phenotypes": {"CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "citalopram"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1199538, "guidelineid": 100413, "drugid": "RxNorm:2556", "implications": {"CYP2C19": "Reduced metabolism when compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose", "classification": "Strong", "phenotypes": {"CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "citalopram"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1199539, "guidelineid": 100413, "drugid": "RxNorm:2556", "implications": {"CYP2C19": "Greatly reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."}, "drugrecommendation": "Consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.", "classification": "Moderate", "phenotypes": {"CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy. Per the FDA warning, citalopram 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation. FDA product labeling additionally cautions that citalopram dose should be limited to 20 mg/day in patients with hepatic impairment, those taking a CYP2C19 inhibitor, and patients greater than 60 years of age. Percent dose adjustments corresponding to percent difference in oral clearances have been calculated/estimated by Stingl et al. (PMID 22565785).", "version": 1, "drug": {"name": "citalopram"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1199540, "guidelineid": 100413, "drugid": "RxNorm:2556", "implications": {"CYP2C19": "Greatly reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."}, "drugrecommendation": "Consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.", "classification": "Moderate", "phenotypes": {"CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy. Per the FDA warning, citalopram 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation. FDA product labeling additionally cautions that citalopram dose should be limited to 20 mg/day in patients with hepatic impairment, those taking a CYP2C19 inhibitor, and patients greater than 60 years of age. Percent dose adjustments corresponding to percent difference in oral clearances have been calculated/estimated by Stingl et al. (PMID 22565785).", "version": 1, "drug": {"name": "citalopram"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1199547, "guidelineid": 100413, "drugid": "RxNorm:321988", "implications": {"CYP2C19": "Greatly reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."}, "drugrecommendation": "Consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.", "classification": "Moderate", "phenotypes": {"CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy. Per the FDA warning, citalopram 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation. FDA product labeling additionally cautions that citalopram dose should be limited to 20 mg/day in patients with hepatic impairment, those taking a CYP2C19 inhibitor, and patients greater than 60 years of age. Percent dose adjustments corresponding to percent difference in oral clearances have been calculated/estimated by Stingl et al. (PMID 22565785).", "version": 1, "drug": {"name": "escitalopram"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1199548, "guidelineid": 100413, "drugid": "RxNorm:321988", "implications": {"CYP2C19": "Greatly reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."}, "drugrecommendation": "Consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.", "classification": "Moderate", "phenotypes": {"CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy. Per the FDA warning, citalopram 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation. FDA product labeling additionally cautions that citalopram dose should be limited to 20 mg/day in patients with hepatic impairment, those taking a CYP2C19 inhibitor, and patients greater than 60 years of age. Percent dose adjustments corresponding to percent difference in oral clearances have been calculated/estimated by Stingl et al. (PMID 22565785).", "version": 1, "drug": {"name": "escitalopram"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1199549, "guidelineid": 100413, "drugid": "RxNorm:321988", "implications": {"CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "No Recommendation", "phenotypes": {"CYP2C19": "Indeterminate"}, "activityscore": {"CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "escitalopram"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200075, "guidelineid": 100413, "drugid": "RxNorm:42355", "implications": {"CYP2D6": "Reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Moderate", "phenotypes": {"CYP2D6": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.0"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "fluvoxamine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200076, "guidelineid": 100413, "drugid": "RxNorm:42355", "implications": {"CYP2D6": "Reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Moderate", "phenotypes": {"CYP2D6": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.75"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "fluvoxamine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200077, "guidelineid": 100413, "drugid": "RxNorm:42355", "implications": {"CYP2D6": "Reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Moderate", "phenotypes": {"CYP2D6": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.5"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "fluvoxamine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200078, "guidelineid": 100413, "drugid": "RxNorm:42355", "implications": {"CYP2D6": "Reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Moderate", "phenotypes": {"CYP2D6": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.25"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "fluvoxamine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200068, "guidelineid": 100413, "drugid": "RxNorm:42355", "implications": {"CYP2D6": "No data available for CYP2D6 ultrarapid metabolizers"}, "drugrecommendation": "No recommendation due to lack of evidence", "classification": "No Recommendation", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "3.0"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3"}, "population": "general", "comments": "Data are lacking describing the effect of CYP2D6 ultrarapid metabolism on fluvoxamine therapy; therefore no dosing recommendations are provided for fluvoxamine use for of CYP2D6 ultrarapid metabolizers. It may be reasonable, though, to select an alternative SSRI not extensively metabolized by CYP2D6 due to the lack of data describing how CYP2D6 ultrarapid metabolizer status influences fluvoxamine therapy.", "version": 1, "drug": {"name": "fluvoxamine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200069, "guidelineid": 100413, "drugid": "RxNorm:42355", "implications": {"CYP2D6": "No data available for CYP2D6 ultrarapid metabolizers"}, "drugrecommendation": "No recommendation due to lack of evidence", "classification": "No Recommendation", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "2.5"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5"}, "population": "general", "comments": "Data are lacking describing the effect of CYP2D6 ultrarapid metabolism on fluvoxamine therapy; therefore no dosing recommendations are provided for fluvoxamine use for of CYP2D6 ultrarapid metabolizers. It may be reasonable, though, to select an alternative SSRI not extensively metabolized by CYP2D6 due to the lack of data describing how CYP2D6 ultrarapid metabolizer status influences fluvoxamine therapy.", "version": 1, "drug": {"name": "fluvoxamine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200070, "guidelineid": 100413, "drugid": "RxNorm:42355", "implications": {"CYP2D6": "Normal metabolism"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "2.25"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "fluvoxamine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200071, "guidelineid": 100413, "drugid": "RxNorm:42355", "implications": {"CYP2D6": "Normal metabolism"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "2.0"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "fluvoxamine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200072, "guidelineid": 100413, "drugid": "RxNorm:42355", "implications": {"CYP2D6": "Normal metabolism"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.75"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "fluvoxamine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200059, "guidelineid": 100413, "drugid": "RxNorm:42355", "implications": {"CYP2D6": "No data available for CYP2D6 ultrarapid metabolizers"}, "drugrecommendation": "No recommendation due to lack of evidence", "classification": "No Recommendation", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22656"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656"}, "population": "general", "comments": "Data are lacking describing the effect of CYP2D6 ultrarapid metabolism on fluvoxamine therapy; therefore no dosing recommendations are provided for fluvoxamine use for of CYP2D6 ultrarapid metabolizers. It may be reasonable, though, to select an alternative SSRI not extensively metabolized by CYP2D6 due to the lack of data describing how CYP2D6 ultrarapid metabolizer status influences fluvoxamine therapy.", "version": 1, "drug": {"name": "fluvoxamine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200060, "guidelineid": 100413, "drugid": "RxNorm:42355", "implications": {"CYP2D6": "No data available for CYP2D6 ultrarapid metabolizers"}, "drugrecommendation": "No recommendation due to lack of evidence", "classification": "No Recommendation", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22655"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655"}, "population": "general", "comments": "Data are lacking describing the effect of CYP2D6 ultrarapid metabolism on fluvoxamine therapy; therefore no dosing recommendations are provided for fluvoxamine use for of CYP2D6 ultrarapid metabolizers. It may be reasonable, though, to select an alternative SSRI not extensively metabolized by CYP2D6 due to the lack of data describing how CYP2D6 ultrarapid metabolizer status influences fluvoxamine therapy.", "version": 1, "drug": {"name": "fluvoxamine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200061, "guidelineid": 100413, "drugid": "RxNorm:42355", "implications": {"CYP2D6": "No data available for CYP2D6 ultrarapid metabolizers"}, "drugrecommendation": "No recommendation due to lack of evidence", "classification": "No Recommendation", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5"}, "population": "general", "comments": "Data are lacking describing the effect of CYP2D6 ultrarapid metabolism on fluvoxamine therapy; therefore no dosing recommendations are provided for fluvoxamine use for of CYP2D6 ultrarapid metabolizers. It may be reasonable, though, to select an alternative SSRI not extensively metabolized by CYP2D6 due to the lack of data describing how CYP2D6 ultrarapid metabolizer status influences fluvoxamine therapy.", "version": 1, "drug": {"name": "fluvoxamine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200062, "guidelineid": 100413, "drugid": "RxNorm:42355", "implications": {"CYP2D6": "No data available for CYP2D6 ultrarapid metabolizers"}, "drugrecommendation": "No recommendation due to lack of evidence", "classification": "No Recommendation", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22654"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654"}, "population": "general", "comments": "Data are lacking describing the effect of CYP2D6 ultrarapid metabolism on fluvoxamine therapy; therefore no dosing recommendations are provided for fluvoxamine use for of CYP2D6 ultrarapid metabolizers. It may be reasonable, though, to select an alternative SSRI not extensively metabolized by CYP2D6 due to the lack of data describing how CYP2D6 ultrarapid metabolizer status influences fluvoxamine therapy.", "version": 1, "drug": {"name": "fluvoxamine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200063, "guidelineid": 100413, "drugid": "RxNorm:42355", "implications": {"CYP2D6": "No data available for CYP2D6 ultrarapid metabolizers"}, "drugrecommendation": "No recommendation due to lack of evidence", "classification": "No Recommendation", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5"}, "population": "general", "comments": "Data are lacking describing the effect of CYP2D6 ultrarapid metabolism on fluvoxamine therapy; therefore no dosing recommendations are provided for fluvoxamine use for of CYP2D6 ultrarapid metabolizers. It may be reasonable, though, to select an alternative SSRI not extensively metabolized by CYP2D6 due to the lack of data describing how CYP2D6 ultrarapid metabolizer status influences fluvoxamine therapy.", "version": 1, "drug": {"name": "fluvoxamine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200064, "guidelineid": 100413, "drugid": "RxNorm:42355", "implications": {"CYP2D6": "No data available for CYP2D6 ultrarapid metabolizers"}, "drugrecommendation": "No recommendation due to lack of evidence", "classification": "No Recommendation", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25"}, "population": "general", "comments": "Data are lacking describing the effect of CYP2D6 ultrarapid metabolism on fluvoxamine therapy; therefore no dosing recommendations are provided for fluvoxamine use for of CYP2D6 ultrarapid metabolizers. It may be reasonable, though, to select an alternative SSRI not extensively metabolized by CYP2D6 due to the lack of data describing how CYP2D6 ultrarapid metabolizer status influences fluvoxamine therapy.", "version": 1, "drug": {"name": "fluvoxamine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200065, "guidelineid": 100413, "drugid": "RxNorm:42355", "implications": {"CYP2D6": "No data available for CYP2D6 ultrarapid metabolizers"}, "drugrecommendation": "No recommendation due to lack of evidence", "classification": "No Recommendation", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653"}, "population": "general", "comments": "Data are lacking describing the effect of CYP2D6 ultrarapid metabolism on fluvoxamine therapy; therefore no dosing recommendations are provided for fluvoxamine use for of CYP2D6 ultrarapid metabolizers. It may be reasonable, though, to select an alternative SSRI not extensively metabolized by CYP2D6 due to the lack of data describing how CYP2D6 ultrarapid metabolizer status influences fluvoxamine therapy.", "version": 1, "drug": {"name": "fluvoxamine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200066, "guidelineid": 100413, "drugid": "RxNorm:42355", "implications": {"CYP2D6": "No data available for CYP2D6 ultrarapid metabolizers"}, "drugrecommendation": "No recommendation due to lack of evidence", "classification": "No Recommendation", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "4.0"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4"}, "population": "general", "comments": "Data are lacking describing the effect of CYP2D6 ultrarapid metabolism on fluvoxamine therapy; therefore no dosing recommendations are provided for fluvoxamine use for of CYP2D6 ultrarapid metabolizers. It may be reasonable, though, to select an alternative SSRI not extensively metabolized by CYP2D6 due to the lack of data describing how CYP2D6 ultrarapid metabolizer status influences fluvoxamine therapy.", "version": 1, "drug": {"name": "fluvoxamine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200067, "guidelineid": 100413, "drugid": "RxNorm:42355", "implications": {"CYP2D6": "No data available for CYP2D6 ultrarapid metabolizers"}, "drugrecommendation": "No recommendation due to lack of evidence", "classification": "No Recommendation", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "3.5"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5"}, "population": "general", "comments": "Data are lacking describing the effect of CYP2D6 ultrarapid metabolism on fluvoxamine therapy; therefore no dosing recommendations are provided for fluvoxamine use for of CYP2D6 ultrarapid metabolizers. It may be reasonable, though, to select an alternative SSRI not extensively metabolized by CYP2D6 due to the lack of data describing how CYP2D6 ultrarapid metabolizer status influences fluvoxamine therapy.", "version": 1, "drug": {"name": "fluvoxamine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200073, "guidelineid": 100413, "drugid": "RxNorm:42355", "implications": {"CYP2D6": "Normal metabolism"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.5"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "fluvoxamine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200079, "guidelineid": 100413, "drugid": "RxNorm:42355", "implications": {"CYP2D6": "Greatly reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."}, "drugrecommendation": "Consider a 25-50% reduction of recommended starting dose and titrate to response or use an alternative drug not metabolized by CYP2D6.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.0"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0"}, "population": "general", "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy. Dose extrapolations based on differences in pharmacokinetic parameters between phenotype groups suggest a 30% dose reduction of fluvoxamine (PMID 22565785). However, a 30% decrease in dose may not be feasible given the dosage forms; therefore, decreasing the starting dose of fluvoxamine by 25-50% should be considered.", "version": 1, "drug": {"name": "fluvoxamine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200080, "guidelineid": 100413, "drugid": "RxNorm:42355", "implications": {"CYP2D6": "n/a"}, "drugrecommendation": "No recommendation", "classification": "No Recommendation", "phenotypes": {"CYP2D6": "Indeterminate"}, "activityscore": {"CYP2D6": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "fluvoxamine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200446, "guidelineid": 100413, "drugid": "RxNorm:32937", "implications": {"CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."}, "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22656"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656"}, "population": "general", "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.", "version": 1, "drug": {"name": "paroxetine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200464, "guidelineid": 100413, "drugid": "RxNorm:32937", "implications": {"CYP2D6": "Reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."}, "drugrecommendation": "Initiate therapy with recommended starting dose", "classification": "Moderate", "phenotypes": {"CYP2D6": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.5"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "paroxetine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200465, "guidelineid": 100413, "drugid": "RxNorm:32937", "implications": {"CYP2D6": "Reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."}, "drugrecommendation": "Initiate therapy with recommended starting dose", "classification": "Moderate", "phenotypes": {"CYP2D6": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.25"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "paroxetine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200447, "guidelineid": 100413, "drugid": "RxNorm:32937", "implications": {"CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."}, "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22655"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655"}, "population": "general", "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.", "version": 1, "drug": {"name": "paroxetine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200448, "guidelineid": 100413, "drugid": "RxNorm:32937", "implications": {"CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."}, "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5"}, "population": "general", "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.", "version": 1, "drug": {"name": "paroxetine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200449, "guidelineid": 100413, "drugid": "RxNorm:32937", "implications": {"CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."}, "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22654"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654"}, "population": "general", "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.", "version": 1, "drug": {"name": "paroxetine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200450, "guidelineid": 100413, "drugid": "RxNorm:32937", "implications": {"CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."}, "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5"}, "population": "general", "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.", "version": 1, "drug": {"name": "paroxetine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200451, "guidelineid": 100413, "drugid": "RxNorm:32937", "implications": {"CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."}, "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25"}, "population": "general", "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.", "version": 1, "drug": {"name": "paroxetine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200452, "guidelineid": 100413, "drugid": "RxNorm:32937", "implications": {"CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."}, "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653"}, "population": "general", "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.", "version": 1, "drug": {"name": "paroxetine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200453, "guidelineid": 100413, "drugid": "RxNorm:32937", "implications": {"CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."}, "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "4.0"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4"}, "population": "general", "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.", "version": 1, "drug": {"name": "paroxetine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200454, "guidelineid": 100413, "drugid": "RxNorm:32937", "implications": {"CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."}, "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "3.5"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5"}, "population": "general", "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.", "version": 1, "drug": {"name": "paroxetine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200455, "guidelineid": 100413, "drugid": "RxNorm:32937", "implications": {"CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."}, "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "3.0"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3"}, "population": "general", "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.", "version": 1, "drug": {"name": "paroxetine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200456, "guidelineid": 100413, "drugid": "RxNorm:32937", "implications": {"CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."}, "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "2.5"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5"}, "population": "general", "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.", "version": 1, "drug": {"name": "paroxetine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200457, "guidelineid": 100413, "drugid": "RxNorm:32937", "implications": {"CYP2D6": "Normal metabolism"}, "drugrecommendation": "Initiate therapy with recommended starting dose", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "2.25"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "paroxetine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200458, "guidelineid": 100413, "drugid": "RxNorm:32937", "implications": {"CYP2D6": "Normal metabolism"}, "drugrecommendation": "Initiate therapy with recommended starting dose", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "2.0"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "paroxetine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200459, "guidelineid": 100413, "drugid": "RxNorm:32937", "implications": {"CYP2D6": "Normal metabolism"}, "drugrecommendation": "Initiate therapy with recommended starting dose", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.75"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "paroxetine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200460, "guidelineid": 100413, "drugid": "RxNorm:32937", "implications": {"CYP2D6": "Normal metabolism"}, "drugrecommendation": "Initiate therapy with recommended starting dose", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.5"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "paroxetine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200461, "guidelineid": 100413, "drugid": "RxNorm:32937", "implications": {"CYP2D6": "Normal metabolism"}, "drugrecommendation": "Initiate therapy with recommended starting dose", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.25"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "paroxetine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200462, "guidelineid": 100413, "drugid": "RxNorm:32937", "implications": {"CYP2D6": "Reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."}, "drugrecommendation": "Initiate therapy with recommended starting dose", "classification": "Moderate", "phenotypes": {"CYP2D6": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.0"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "paroxetine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200463, "guidelineid": 100413, "drugid": "RxNorm:32937", "implications": {"CYP2D6": "Reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."}, "drugrecommendation": "Initiate therapy with recommended starting dose", "classification": "Moderate", "phenotypes": {"CYP2D6": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.75"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "paroxetine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200466, "guidelineid": 100413, "drugid": "RxNorm:32937", "implications": {"CYP2D6": "Greatly reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."}, "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 or if paroxetine use warranted, consider a 50% reduction of recommended starting dose and titrate to response.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.0"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0"}, "population": "general", "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.", "version": 1, "drug": {"name": "paroxetine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200467, "guidelineid": 100413, "drugid": "RxNorm:32937", "implications": {"CYP2D6": "n/a"}, "drugrecommendation": "No recommendation", "classification": "No Recommendation", "phenotypes": {"CYP2D6": "Indeterminate"}, "activityscore": {"CYP2D6": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "paroxetine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200558, "guidelineid": 100413, "drugid": "RxNorm:36437", "implications": {"CYP2C19": "Increased metabolism when compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose. If patient does not respond to recommended maintenance dosing, consider alternative drug not predominantly metabolized by CYP2C19.", "classification": "Optional", "phenotypes": {"CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.", "version": 1, "drug": {"name": "sertraline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200559, "guidelineid": 100413, "drugid": "RxNorm:36437", "implications": {"CYP2C19": "Increased metabolism when compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose. If patient does not respond to recommended maintenance dosing, consider alternative drug not predominantly metabolized by CYP2C19.", "classification": "Optional", "phenotypes": {"CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.", "version": 1, "drug": {"name": "sertraline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200560, "guidelineid": 100413, "drugid": "RxNorm:36437", "implications": {"CYP2C19": "Normal metabolism"}, "drugrecommendation": "Initiate therapy with recommended starting dose", "classification": "Strong", "phenotypes": {"CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "sertraline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200561, "guidelineid": 100413, "drugid": "RxNorm:36437", "implications": {"CYP2C19": "Reduced metabolism when compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose", "classification": "Strong", "phenotypes": {"CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "sertraline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200562, "guidelineid": 100413, "drugid": "RxNorm:36437", "implications": {"CYP2C19": "Reduced metabolism when compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose", "classification": "Strong", "phenotypes": {"CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "sertraline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200563, "guidelineid": 100413, "drugid": "RxNorm:36437", "implications": {"CYP2C19": "Greatly reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."}, "drugrecommendation": "Consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.", "classification": "Optional", "phenotypes": {"CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy. Percent dose adjustments corresponding to percent difference in oral clearances have been calculated/estimated by Stingl et al. (PMID 22565785).", "version": 1, "drug": {"name": "sertraline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200564, "guidelineid": 100413, "drugid": "RxNorm:36437", "implications": {"CYP2C19": "Greatly reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."}, "drugrecommendation": "Consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.", "classification": "Optional", "phenotypes": {"CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy. Percent dose adjustments corresponding to percent difference in oral clearances have been calculated/estimated by Stingl et al. (PMID 22565785).", "version": 1, "drug": {"name": "sertraline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}, {"id": 1200565, "guidelineid": 100413, "drugid": "RxNorm:36437", "implications": {"CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "No Recommendation", "phenotypes": {"CYP2C19": "Indeterminate"}, "activityscore": {"CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "sertraline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors"}}]